-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptevo Therapeutics Q3 2026 Net Loss Narrows 13% Year Over Year to $6.5 Million

PUBT·11/16/2026 13:32:48
Listen to the news
Aptevo Therapeutics Q3 2026 Net Loss Narrows 13% Year Over Year to $6.5 Million
  • Aptevo Therapeutics’ third-quarter 2026 net loss narrowed 13% year over year to $6.5 million.
  • Cash and cash equivalents fell 15% from June 30 to $8.3 million at September 30, 2026.
  • An August warrant inducement and private placement generated approximately $4.5 million in gross proceeds.
  • Mipletamig combined with venetoclax and azacitidine achieved a 79% remission rate among 14 evaluable patients with TP53-mutated AML.
  • RAINIER Phase 1b dose optimization completion is targeted for year-end 2026, with regulatory interaction planned for the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611160830ACCESSWRNAPR_____1250832) on November 16, 2026, and is solely responsible for the information contained therein.